



Novel Therapeutic Approaches for Colorectal Cancer

Guest Editors:

**Prof. Dr. Marzia Bruna
Gariboldi**

Department of Biotechnology
and Life Sciences, University of
Insubria, Varese, Italy

Dr. Greta Varchi

Institute of the Organic Synthesis
and Photoreactivity, Italian
National Research Council, 40129
Bologna, Italy

Dr. Claudia Ferroni

Institute for the Organic
Synthesis and Photoreactivity
(ISOF), National Research Council
(CNR), 40129 Bologna, Italy

Deadline for manuscript
submissions:

closed (31 July 2023)

Message from the Guest Editors

Dear Colleagues,

Colorectal cancer (CRC) is the third most common cancer worldwide, with a 5-year survival rate (all stages) of 64%. Early-stage, non-metastatic CRC is primarily managed surgically, followed by adjuvant systemic chemotherapy or radiotherapy, while the first-line treatment for metastatic CRC usually involves systemic chemotherapy with capecitabine, irinotecan, oxaliplatin, and 5-fluorouracil, alone or in combination with biologics or immunotherapeutic drugs.

However, the onset of multidrug-resistant mechanisms and severe side effects and the poor quality of life induced by these treatments have prompted the development of novel and potentially more effective therapeutic options for CRC treatment.

This Special Issue aims to collect original research articles and comprehensive reviews on the most recent advances concerning CRC treatment, including (but not limited to) the following: novel small anticancer molecules; epigenetic drugs; nanotechnology-based combination therapies; targeted therapies including external-stimuli-activated approaches; drug repurposing; immunotherapeutic approaches.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)